Showing 1491-1500 of 2656 results for "".
- Your Patient Plans to Travel Despite COVID-19 Risk? Here’s the Latest CDC Guidance to Sharehttps://modernod.com/news/your-patient-plans-to-travel-despite-covid-19-risk-heres-the-latest-cdc-guidance-to-share/2478627/Make no mistake: Federal officials recommend the American public stay home over the upcoming holidays in order to stem the spread of the COVID-19 pandemic. Cases of COVID-19 are surging across the country and flooding—in some cases, overwhelming—hospitals, pushing many to postpone elective
- FDA Approves Eyenovia’s IND Application for MicroLine for Presbyopia, Allowing for Phase 3 Trialshttps://modernod.com/news/fda-approves-eyenovias-ind-application-for-microline-for-presbyopia-allowing-for-phase-3-trials/2478620/Eyenovia announced that the FDA has accepted its investigational new drug (IND) application for MicroLine, a proprietary pilocarpine formulation for the improvement in near vision in patients with presbyopia. The company intends to initiate the phase 3 VISION program, beginning with the VISION-1
- Moderna’s mRNA COVID-19 Vaccine 94.1% Effective at Final Analysishttps://modernod.com/news/modernas-mrna-covid-19-vaccine-94-1-effective-at-final-analysis/2478596/Moderna announced Monday that the primary efficacy analysis of the phase 3 COVE study showed that its experimental mRNA-based COVID-19 vaccine mRNA-1273 had an efficacy rate of 94.1%, confirming the level observed at the first interim analysis. The company noted that the latest data were based on
- Data Confirm Immune Response From AstraZeneca’s COVID-19 Vaccine in Elderlyhttps://modernod.com/news/data-confirm-immune-response-from-astrazenecas-covid-19-vaccine-in-elderly/2478582/Study results published in The Lancet suggest that the chimpanzee adenovirus-vectored COVID-19 vaccine being developed by AstraZeneca and the University of Oxford is able to produce a strong immune response in older adults, whilst being better tolerated in this age group than compared wi
- Despite Impressive Data, FDA’s Coronavirus Vaccine Reviews Will Take Weeks, Not Days, Official Sayshttps://modernod.com/news/despite-impressive-data-fdas-coronavirus-vaccine-reviews-will-take-weeks-not-days-official-says/2478574/As leading COVID-19 vaccines post positive phase 3 data and near FDA submissions, the agency official in charge of reviewing vaccines is emphasizing transparency and patience during the high-stakes process, according to a FiercePharma
- Pfizer, BioNTech’s COVID-19 Vaccine Shows 95% Efficacy Rate at Final Analysishttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-shows-95-efficacy-rate-at-final-analysis/2478571/Pfizer and BioNTech announced Wednesday that their mRNA-based COVID-19 vaccine candidate BNT162b2 demonstrated an efficacy rate of 95% at the final efficacy analysis of a phase 3 study. The companies noted the primary objective analysis is based on 170 cases of COVID-19, of which 162 cases were o
- AstraZeneca’s Calquence Fails to Help Patients Hospitalized With COVID-19 Respiratory Symptomshttps://modernod.com/news/astrazenecas-calquence-fails-to-help-patients-hospitalized-with-covid-19-respiratory-symptoms/2478544/AstraZeneca announced that the phase 2 CALAVI studies investigating the addition of Calquence (acalabrutinib) to best supportive care (BSC) in patients hospitalized with respiratory symptoms of COVID-19 failed to meet their primary efficacy endpoint. Results showed that the BTK inhibitor did not
- EU Seals Deal For Up to 300 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/eu-seals-deal-for-up-to-300-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478528/The European Commission on Wednesday said it has finalized an advance purchase agreement with Pfizer and BioNTech for the initial supply of 200 million doses of their experimental COVID-19 vaccine, with an option to request up to a 100 million more. The announcement comes days after the companies
- FDA Authorizes Lilly’s Antibody Therapy Bamlanivimab for Recently Diagnosed COVID-19https://modernod.com/news/fda-authorises-lillys-antibody-therapy-bamlanivimab-for-recently-diagnosed-covid-19/2478512/Eli Lilly announced Monday that the FDA has granted its emergency-use authorization (EUA) request for the investigational neutralizing antibody bamlanivimab. The AbCellera-partnered therapy, also known as LY-CoV555, is authorized to treat recently diagnosed, mild-to-moderate COVID-19 in patients
- Health Care Experts Named to Biden’s COVID-19 Advisory Boardhttps://modernod.com/news/health-care-experts-named-to-bidens-covid-19-advisory-board/2478511/Former U.S. Surgeon General Vivek Murthy, MD, and former FDA Commissioner David Kessler, MD, will be among the public health leaders guiding the transition team for President-elect Joe Biden regarding COVID-19, according to a FierceHealthcare